@prefix this: <
http://www.tkuhn.ch/bel2nanopub/RAcwgcn30XhK6ctzvQP_Mp0ORN1hD1aLNjvwQ4-E7S3-c
> .
@prefix sub: <
http://www.tkuhn.ch/bel2nanopub/RAcwgcn30XhK6ctzvQP_Mp0ORN1hD1aLNjvwQ4-E7S3-c#
> .
@prefix beldoc: <
http://resource.belframework.org/belframework/1.0/knowledge/large_corpus.bel
> .
@prefix rdfs: <
http://www.w3.org/2000/01/rdf-schema#
> .
@prefix rdf: <
http://www.w3.org/1999/02/22-rdf-syntax-ns#
> .
@prefix xsd: <
http://www.w3.org/2001/XMLSchema#
> .
@prefix dct: <
http://purl.org/dc/terms/
> .
@prefix dce: <
http://purl.org/dc/elements/1.1/
> .
@prefix pav: <
http://purl.org/pav/
> .
@prefix np: <
http://www.nanopub.org/nschema#
> .
@prefix belv: <
http://www.selventa.com/vocabulary/
> .
@prefix prov: <
http://www.w3.org/ns/prov#
> .
@prefix schem: <
http://resource.belframework.org/belframework/1.0/namespace/selventa-legacy-chemical-names/
> .
@prefix species: <
http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=
> .
@prefix occursIn: <
http://purl.obolibrary.org/obo/BFO_0000066
> .
@prefix pubmed: <
http://www.ncbi.nlm.nih.gov/pubmed/
> .
@prefix orcid: <
http://orcid.org/
> .
sub:Head
{
this:
np:hasAssertion
sub:assertion
;
np:hasProvenance
sub:provenance
;
np:hasPublicationInfo
sub:pubinfo
;
a
np:Nanopublication
.
}
sub:assertion
{
sub:_1
occursIn:
species:9606
;
rdf:object
schem:serum%20fatty%20acid
;
rdf:predicate
belv:decreases
;
rdf:subject
schem:serum%20insulin
;
a
rdf:Statement
.
sub:assertion
rdfs:label
"a(SCHEM:\"serum insulin\") -| a(SCHEM:\"serum fatty acid\")" .
}
sub:provenance
{
beldoc:
dce:description
"Approximately 61,000 statements." ;
dce:rights
"Copyright (c) 2011-2012, Selventa. All rights reserved." ;
dce:title
"BEL Framework Large Corpus Document" ;
pav:authoredBy
sub:_3
;
pav:version
"1.4" .
sub:_2
prov:value
"Furthermore, studies of patients with insulin-secreting tumors suggest that inhibition of hepatic glucose production is the major mechanism whereby insulin lowers plasma glucose in the fasting state. Insulin first acts directly upon adipose tissue to suppress lipolysis and decrease levels of circulating free fatty acids. This, in turn, may cause the inhibition of hepatic glucose production" ;
prov:wasQuotedFrom
pubmed:10199397
.
sub:_3
rdfs:label
"Selventa" .
sub:assertion
prov:hadPrimarySource
pubmed:10199397
;
prov:wasDerivedFrom
beldoc:
,
sub:_2
.
}
sub:pubinfo
{
this:
dct:created
"2014-07-03T14:29:46.736+02:00"^^
xsd:dateTime
;
pav:createdBy
orcid:0000-0001-6818-334X
,
orcid:0000-0002-1267-0234
.
}